|
Schering
Expected to Present Results of Phase 1 Clinical Study of Experimental
Oral HCV Protease Inhibitor SCH 503034 at 56th AASLD Conference
Researchers
at several companies have been evaluating various compounds
that target the protease enzyme of the hepatitis C virus.
Successful production of such a drug could be a breakthrough
development for the treatment of chronic hepatitis C similar
to that seen with the development of the HIV protease inhibitors.
At
the upcoming 56th
annual meeting of the American Association for the Study of
Liver Diseases (56th AASLD) in San
Francisco (November 11-15, 2005), investigators from Schering-Plough
will present new clinical data on their promising experimental
HCV protease inhibitor SCH 503034.
The
data represent results of Phase I studies of SCH 503034 as
monotherapy and in combination with peginterferon
alfa-2b (PegIntron) in genotype
1 patients who are non responders
to peginterferon/ribavirin combination therapy.
These Phase 1 studies were conducted with a oral (capsule)
formulation of the drug that is suitable for use in larger
clinical studies and potentially for commercial development
of the drug.
Schering
will initiate a Phase II dose-finding study of SCH 503034
that will provide the dosing information required to conduct
a complete clinical development program. The full study title
is “PEG-Intron/Rebetol vs PEG-Intron/SCH 503034 with and
without Ribavirin in Chronic Hepatitis C HCV-1 Peginterferon
Alfa/Ribavirin Nonresponders: A SCH 503034 Dose-Finding
Phase 2 Study.” Please note that this study is not yet
recruiting patients for enrollment. Look for an announcement
soon on this website of the date for open recruitment, location
of study sites, and study entry and exclusion criteria.
09/23/05
Source
Schering-Plough
|
